The vitamin K shot is a single injection given to newborns shortly after birth to prevent a potentially fatal bleeding condition. Babies are born with very little vitamin K, a nutrient essential for blood clotting, and without supplementation, they can develop uncontrolled bleeding in the brain, intestines, or other organs during the first six months of life. The shot has been standard practice in the United States since the American Academy of Pediatrics first recommended it in 1961.
Why Babies Are Born With Low Vitamin K
Vitamin K doesn’t cross the placenta efficiently during pregnancy, so newborns arrive with very little of it in their system. After birth, breast milk provides only small amounts. This means exclusively breastfed infants often have vitamin K levels below adult norms from six weeks through six months of age.
This matters because vitamin K activates several proteins the body needs to form blood clots. Without enough of it, even minor internal injuries that a healthy adult’s body would handle automatically can turn into dangerous, uncontrolled bleeding. Adults get most of their vitamin K from leafy green vegetables and from bacteria in their gut, but newborns haven’t yet built up either source.
What Vitamin K Deficiency Bleeding Looks Like
The condition the shot prevents is called vitamin K deficiency bleeding, or VKDB. It comes in three forms depending on when it appears.
Early-onset VKDB happens within the first 24 hours of life. It’s most common in babies whose mothers took certain medications during pregnancy, particularly anti-seizure drugs that interfere with vitamin K metabolism. Bleeding often occurs inside the skull or abdomen, and outcomes are poor.
Classical VKDB shows up between days two and seven. Babies may bleed from the umbilical stump, the nose, the gastrointestinal tract, or the skin. Circumcision wounds may also bleed excessively. This form generally has a good prognosis because the bleeding sites are more accessible and easier to treat.
Late-onset VKDB is the most dangerous form that the shot specifically targets in otherwise healthy babies. It strikes between one week and six months of age, most commonly between weeks two and eight. Somewhere between 30% and 60% of affected infants have bleeding within the brain. Mortality runs as high as 20% to 50%, and in a large Japanese study of 427 infants with the condition, 14.5% died and 40% of survivors had severe neurological damage. One of the most alarming features of late-onset VKDB is that warning bleeds are rare. The first sign of a problem can be a life-threatening brain hemorrhage.
How Effective the Shot Is
A single intramuscular injection reduces late-onset VKDB by 98%. Without the shot, the incidence of early and classical VKDB ranges from 0.25% to 1.7% of all births, and late-onset VKDB occurs in roughly 4.4 to 7.2 per 100,000 infants. Those numbers sound small, but the consequences are severe enough that the risk calculus is straightforward. Infants who don’t receive the injection are an estimated 81 times more likely to develop late-onset VKDB than those who do.
What the Shot Contains and How It’s Given
The injection is a small dose of a form of vitamin K called phytonadione. Babies weighing more than about 3.3 pounds receive 1.0 mg; smaller newborns get 0.5 mg. It’s given as an intramuscular injection, typically in the thigh, within the first six hours after birth. The muscle acts as a slow-release reservoir, gradually releasing vitamin K into the bloodstream over weeks and bridging the gap until the baby can build up stores through feeding and gut bacteria.
Side Effects and Safety
Side effects are minimal. The most common is mild irritation at the injection site, the same kind of soreness any shot can cause. Severe allergic reactions like anaphylaxis are extremely rare.
A 1990 study published in the British Medical Journal raised a concern about a possible link between vitamin K injections and childhood cancer. That finding prompted extensive follow-up research across multiple countries. None of those studies found any association, the original results were never replicated, and the medical consensus today is that the injection is safe.
Oral Vitamin K as an Alternative
Some parents ask about giving vitamin K by mouth instead of injection. Oral vitamin K does improve clotting markers in the first week of life, but it’s considerably less reliable at preventing late-onset VKDB. The core problem is that a single oral dose isn’t enough. Effective oral regimens require multiple doses spread over weeks, with the most common schedule being three doses: one after the first feeding, another at two to four weeks, and a third at six to eight weeks. Some protocols call for weekly dosing throughout the breastfeeding period.
Adherence is the weak link. If a family misses even one dose, protection drops significantly. Because multiple-dose oral regimens depend entirely on parents remembering every dose on schedule, and because late-onset VKDB can appear without warning signs, pediatric guidelines in the U.S. and Canada recommend the single injection as the most reliable option.
Signs of VKDB in Infants
If your baby did not receive the vitamin K shot, or if you’re unsure whether they did, it helps to know what bleeding from vitamin K deficiency can look like. In the first week, watch for unusual bruising, bleeding from the umbilical cord that doesn’t stop, or blood in the stool. After the first week, symptoms of late-onset VKDB can include sudden irritability, vomiting, seizures, or unusual sleepiness, all of which can signal bleeding in the brain. A bulging soft spot on the top of the head is another red flag. Because late-onset VKDB rarely gives warning signs before a major bleed, any of these symptoms in a young infant warrants immediate medical attention.